Showing posts with label Celgene. Show all posts
Showing posts with label Celgene. Show all posts

8/8/10

Top BioPharma Pipeline Plays August 2010

Image representing Celgene as depicted in Crun...Image via CrunchBase Stocks currently on my Watchlist for top BioPharma plays in the near future.

1. Valeant Pharmaceuticals (NYSE:VRX)

Biotechnology Research Report on Valeant's Potiga

On August 11, 2010, we expect the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee to review the marketing application of Valeant Pharmaceuticals International’s (VRX) Potiga (formerly known as Retigabine), designed for the treatment of partial-onset seizures in epilepsy patients who have become refractory (failing to show response to prior therapy) to anti-epilepsy drugs (AEDs).

Nanotechnology Enables Precise Cancer Targeting

 
Image representing Abraxis BioScience as depic...






 I highly recommend reading about Nanoparticles in cancer targeting therapies. This was posted in GEN (Genetic Engineering and Biotechnology News) Many Stock Ideas here. I will post more on each company soon. This is the future of Biotechnology.

Nanotechnology Enables Precise Cancer Targeting
Patricia F. Dimond, Ph.D.

Second-generation nanotherapeutics to treat cancer have drawn attention and funding as companies move to improve the efficacy of these treatments and expand their applications. Generally in the size range of 1–100 nm, these drugs have emerged as novel antitumor agents because they have the potential to deliver high concentrations of drugs to cancer cells and cause less toxicity than systemically administered drugs.